In asymptomatic or minimally symptomatic mCRPC patients, treat them early with PROVENGE Immunotherapy
- To stimulate your mCRPC patients’ immune systems while they have a lower tumor burden1
- The NCCN recommends PROVENGE as first-line treatment for asymptomatic or minimally symptomatic mCRPC2
- Updated NCCN guidelines support the use of PROVENGE before enzalutamide, abiraterone, chemotherapy, and other treatments in asymptomatic or minimally symptomatic mCRPC patients who have progressed2
- PROVENGE does not preclude the use of subsequent therapies3,4
Most CRPC patients fit in the PROVENGE window at the time of metastatic diagnosis
Treat early — make sure your patients take advantage of the PROVENGE window
Keep in mind that if your patient:
He is a candidate for PROVENGE3
Learn about Mike's Experience with PROVENGE
- Data on file. Dendreon Corporation.
- National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer V1.2015. www.nccn.org. Accessed December 10, 2014.
- Provenge [prescribing information]. Seattle, WA: Dendreon Corporation; 2014.
- Cheever MA, Higano CS. PROVENGE (sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clin Cancer Res. 2011;17(11):3520-3526.
- Hotte SJ, Saad F. Current management of castrate-resistant prostate cancer. Curr Oncol. 2010;17(S2):S72-S79.
- Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008;26(7):1148-1159.